Results 231 to 240 of about 635,069 (409)

Editorial: The role of vitamin D in metabolic and cardiovascular health, volume II. [PDF]

Front Nutr
Šarac I, Debeljak Martačić J, Hart K, Milešević J.   +3 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Barriers to clinical cancer research participation: moving from inclusion to engagement when considering European migrants' recruitment. [PDF]

Trials
Millet N, Brzeska M, Czyznikowska B, Postavaru GI, Silina I, Darko N, Moss EL.   +6 more
europepmc   +1 more source

Topics in clinical trial management

, 2004
Bridget Anne Kirwan
openalex   +1 more source

Proceedings of the University of Pennsylvania 6th annual conference on statistical issues in clinical trials: Dynamic treatment regimes

Clinical Trials, 2014
J. Ellenberg, S. Ellenberg
semanticscholar   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Assessing the carbon footprint of French academic clinical trials using the NIHR method. [PDF]

BMJ Open
Auriault C, Tching-Sin M, Biron L, Faurel-Paul E, Flet L.   +4 more
europepmc   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Are trial participants adequately safeguarded by the ethics committees – the Indian scenario?

Frontiers in Pharmacology, 2014
Karan eThakkar, Dr Gauri eBilla
doaj   +1 more source

Recruitment to clinical trials: a meta-ethnographic synthesis of studies of reasons for participation

Journal of Health Services Research and Policy, 2013
S. McCann, M. Campbell, V. Entwistle
semanticscholar   +1 more source